Crossject (ALCJ) - Net Assets
Based on the latest financial reports, Crossject (ALCJ) has net assets worth €-4.87 Million EUR (≈ $-5.69 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€30.43 Million ≈ $35.58 Million USD) and total liabilities (€35.30 Million ≈ $41.27 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check ALCJ intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €-4.87 Million |
| % of Total Assets | -16.0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | -177.47% |
| Growth Volatility | 506.54 |
Crossject - Net Assets Trend (2010–2025)
This chart illustrates how Crossject's net assets have evolved over time, based on quarterly financial data. See Crossject (ALCJ) defensive interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Crossject (2010–2025)
The table below shows the annual net assets of Crossject from 2010 to 2025. For live valuation and market cap data, see how much is Crossject worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €-4.87 Million ≈ $-5.69 Million |
-82.12% |
| 2024-12-31 | €-2.67 Million ≈ $-3.13 Million |
+49.27% |
| 2023-12-31 | €-5.27 Million ≈ $-6.16 Million |
-296.17% |
| 2022-12-31 | €2.69 Million ≈ $3.14 Million |
+149.01% |
| 2021-12-31 | €-5.48 Million ≈ $-6.41 Million |
-384.99% |
| 2020-12-31 | €-1.13 Million ≈ $-1.32 Million |
-137.50% |
| 2019-12-31 | €3.01 Million ≈ $3.52 Million |
+82.16% |
| 2018-12-31 | €1.65 Million ≈ $1.93 Million |
-72.81% |
| 2017-12-31 | €6.09 Million ≈ $7.11 Million |
-3.15% |
| 2016-12-31 | €6.28 Million ≈ $7.35 Million |
-28.57% |
| 2015-12-31 | €8.80 Million ≈ $10.29 Million |
-39.26% |
| 2014-12-31 | €14.48 Million ≈ $16.93 Million |
+1428.46% |
| 2013-12-31 | €947.65K ≈ $1.11 Million |
+149.75% |
| 2012-12-31 | €-1.90 Million ≈ $-2.23 Million |
+11.29% |
| 2011-12-31 | €-2.15 Million ≈ $-2.51 Million |
+74.40% |
| 2010-12-31 | €-8.39 Million ≈ $-9.81 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Crossject's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1051976100.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €5.22 Million | % |
| Other Comprehensive Income | €892.00K | % |
| Other Components | €7.77 Million | % |
| Total Equity | €-4.87 Million | 100.00% |
Crossject Competitors by Market Cap
The table below lists competitors of Crossject ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Grupo Ortiz Properties Socimi
MC:YGOP
|
$101.93 Million |
|
Thai Optical Group Public Company Limited
BK:TOG
|
$102.01 Million |
|
Kino Polska TV SA
WAR:KPL
|
$102.01 Million |
|
Mdevice
KQ:226590
|
$102.01 Million |
|
Luda Technology Group Limited
NYSE MKT:LUD
|
$101.88 Million |
|
Piscines Desjoyaux SA
PA:ALPDX
|
$101.87 Million |
|
District Metals Corp
V:DMX
|
$101.87 Million |
|
Lyko Group A
ST:LYKO-A
|
$101.82 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Crossject's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -2,673,000 to -4,873,000, a change of -2,200,000.
- Net loss of 10,367,000 reduced equity.
- Share repurchases of 369,000 reduced equity.
- New share issuances of 4,814,620 increased equity.
- Other comprehensive income decreased equity by 79,999.
- Other factors increased equity by 3,801,379.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-10.37 Million | -212.74% |
| Share Repurchases | €369.00K | -7.57% |
| Share Issuances | €4.81 Million | +98.8% |
| Other Comprehensive Income | €-80.00K | -1.64% |
| Other Changes | €3.80 Million | +78.01% |
| Total Change | €- | % |
Book Value vs Market Value Analysis
This analysis compares Crossject's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-12-31 | €-1.89 | €1.89 | x |
| 2011-12-31 | €-0.48 | €1.89 | x |
| 2012-12-31 | €-0.43 | €1.89 | x |
| 2013-12-31 | €0.18 | €1.89 | x |
| 2014-12-31 | €2.18 | €1.89 | x |
| 2015-12-31 | €1.32 | €1.89 | x |
| 2016-12-31 | €0.86 | €1.89 | x |
| 2017-12-31 | €0.68 | €1.89 | x |
| 2018-12-31 | €0.12 | €1.89 | x |
| 2019-12-31 | €0.15 | €1.89 | x |
| 2020-12-31 | €-0.05 | €1.89 | x |
| 2021-12-31 | €-0.24 | €1.89 | x |
| 2022-12-31 | €0.06 | €1.89 | x |
| 2023-12-31 | €-0.14 | €1.89 | x |
| 2024-12-31 | €-0.06 | €1.89 | x |
| 2025-12-31 | €-0.09 | €1.89 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Crossject utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-122.22%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | 0.00% | -2058.76% | 0.07x | 0.00x | €-3.28 Million |
| 2011 | 0.00% | 237.75% | 0.22x | 0.00x | €1.76 Million |
| 2012 | 0.00% | -261.88% | 0.14x | 0.00x | €-735.29K |
| 2013 | -192.33% | -194.74% | 0.17x | 5.96x | €-1.92 Million |
| 2014 | -29.94% | -313.04% | 0.08x | 1.27x | €-5.78 Million |
| 2015 | -64.64% | -358.57% | 0.11x | 1.58x | €-6.57 Million |
| 2016 | -106.03% | -468.32% | 0.10x | 2.27x | €-7.29 Million |
| 2017 | -125.06% | -235.32% | 0.18x | 2.91x | €-8.22 Million |
| 2018 | -647.41% | -438.26% | 0.12x | 12.18x | €-10.88 Million |
| 2019 | -238.02% | -1434.74% | 0.02x | 8.13x | €-7.48 Million |
| 2020 | 0.00% | -203.22% | 0.14x | 0.00x | €-9.73 Million |
| 2021 | 0.00% | -1184.87% | 0.03x | 0.00x | €-10.19 Million |
| 2022 | -552.05% | -1169.50% | 0.03x | 16.26x | €-11.36 Million |
| 2023 | 0.00% | -5957.24% | 0.01x | 0.00x | €-8.11 Million |
| 2024 | 0.00% | -310.94% | 0.13x | 0.00x | €-12.53 Million |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | €-9.88 Million |
Industry Comparison
This section compares Crossject's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $439,232,556
- Average return on equity (ROE) among peers: -13.02%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Crossject (ALCJ) | €-4.87 Million | 0.00% | N/A | $101.91 Million |
| I.Ceram SA (ALICR) | $1.85 Million | -41.63% | 1.92x | $155.73K |
| Safe Orthopaedics SA (ALSAF) | $-202.35 Million | 0.00% | 0.00x | $130.30K |
| Spineway (ALSPW) | $4.62 Million | -36.05% | 1.43x | $4.57 Million |
| Amplitude Surgical SAS (AMPLI) | $22.40 Million | -9.01% | 4.82x | $299.85 Million |
| Sartorius Stedim Biotech SA (DIM) | $879.45 Million | 18.32% | 0.60x | $15.98 Billion |
| EssilorLuxottica S. A. (EL) | $2.37 Billion | 16.16% | 0.72x | $93.95 Billion |
| Bonyf NV (MLBON) | $2.68 Million | -38.97% | 0.15x | $2.48 Million |
About Crossject
Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, needle-free, pre-filled, single-use auto-injector. Its product pipeline includes Midazolam for epileptic seizure; Naloxone for opioid overdose; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster he… Read more